 CAMBRIDGE, Mass., March 23, 2021 GLOBE NEWSWIRE -- Solid Biosciences Inc., Nasdaq: SLDB a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy Duchenne, today announced the closing of its previously announced underwritten public offering of 25,000,000 shares of its common stock at a public offering price of 5.75 per share, including 3,260,869 shares sold pursuant to the full exercise of the underwriters option to purchase additional shares. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering expenses, were approximately 143.8 million. 